Germany-based medical technology company B. Braun has completed the acquisition of True Digital Surgery (TDS) for an undisclosed amount.
Based in Goleta, California, TDS is a medical equipment manufacturer with expertise in digital robotic-assisted 3D surgical microscopy.聽B. Braun held a minority stake in TDS before the acquisition.
The acquisition enables B. Braun’s surgical division, Aesculap, to leverage the TDS team鈥檚 expertise in advancing the development of the Aesculap AEOS, a robotic digital microscope used in neurosurgery, spinal surgery, and ear, nose, and throat (ENT) surgery.
B. Braun said that the strategic move aligns with its efforts to strengthen its position in the digital microsurgery field.
B. Braun Aesculap surgical division executive board member Jens von Lackum said: 鈥淭his strategic move enables us to integrate the cutting-edge technology and innovative capabilities of TDS.
鈥淏y combining the best of both worlds, we can continue to provide our customers with best-in-class systems in robotic-assisted 3D microsurgery.”
According to B. Braun, the market for high-end microsurgery in the neuro, spine, and ENT sectors is moving from traditional analogue microscopes to digital exoscopes.
The new technologies offer improved visualisation at challenging angles and enable surgeons to operate while viewing 3D monitors, reducing physical strain.
Incorporating agile methods, TDS is focused on developing technology that improves surgical precision and outcomes.
B. Braun plans to continue operating TDS as a technological centre hub in Goleta.
The deal is expected to help TDS and its workforce focus on their core areas of expertise, fostering innovation and the integration of cutting-edge advanced technologies.
True Digital Surgery’s former CEO and board chairman Aidan Foley said: 鈥淭his merger with such a highly respected healthcare organisation as B. Braun represents an exciting new milestone for True Digital Surgery and is a natural extension of the successful partnership we’ve enjoyed for several years.
鈥淭he combination of our groundbreaking technologies with B. Braun’s access to the global healthcare market represents an incomparable opportunity for both companies to further improve the lives of patients and medical professionals the world over.鈥�
Last year, B Braun secured 510(k) clearance from the US Food and Drug Administration (FDA) for its Introcan Safety 2 Deep Access IV Catheter.
